ArticleFrontiers in immunology2026
Circulating IL-17A accumulation reflects effective target blockade with secukinumab in spondyloarthritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate the dynamics of IL-17A levels in patients with spondyloarthritis (SpA) treated with secukinumab and to determine the relationship between circulating IL-17A forms and clinical response. Methods: We analyzed serum IL-17A levels in 33 samples from 11 SpA patients using the highly sensitive proximity extension assay (PEA) at baseline and after 6 and 12 months of secukinumab treatment. Clinical parameters including ASDAS and CRP were recorded. To distinguish free IL- 17A from secukinumab-bound IL-17A, we developed an innovative IgG column-based assay that separates free cytokine from antibody-conjugated fractions. Results: Serum IL-17A levels significantly increased at 6 and 12 months post-secukinumab treatment. This increase correlated negatively with ASDAS and CRP, indicating better clinical response. Analysis showed that the rise was mainly due to the secukinumab-bound IL-17A fraction, while free IL-17A levels remained stable. Conclusion: Our study reveals that the elevated IL-17A levels detected after secukinumab treatment primarily represent the antibody-conjugated form rather than free cytokine. This conjugated fraction is associated with improved clinical outcomes, suggesting it could serve as a biomarker for therapeutic efficacy. The novel IgG column-based assay provides a valuable tool for differentiating cytokine forms in patients undergoing monoclonal antibody therapies, with potential applications beyond SpA. These findings advance understanding of IL-17A dynamics during treatment and open new avenues for personalized monitoring and management in autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.